SLC2A1 and cancer: Our data suggest that targeting the Glut1 pathway may be a safe, inexpensive, and rapidly implementable treatment option for AGN, since highly selective Glut1 inhibitors, such as BAY-876, are currently in use for preclinical studies in cancer (42).